Professor Mike Clarke
- Director of the Northern Ireland Clinical Trials Unit
- Northern Ireland Methodology Hub Lead, Queen’s University, Belfast
Professor Mike Clarke has nearly 30 years’ experience in the design and conduct of rigorous assessments of the effects of interventions through the use of randomised trials and systematic reviews. He joined CTSU in 1989 following a BA in chemistry and while finishing his DPhil on the history and epidemiology of suicide at the University of Oxford. Since then, he has been part of the Secretariat for the breast cancer overview, with a particular focus on the effects of ovarian ablation or suppression for women with early breast cancer. He was Director of the UK Cochrane Centre from 2002 to 2011 and now leads the Northern Ireland Methodology Hub at Queen’s University, Belfast and is Director of the Northern Ireland Clinical Trials Unit.
Identifying trial recruitment uncertainties using a James Lind Alliance Priority Setting Partnership - the PRioRiTy (Prioritising Recruitment in Randomised Trials) study.
Healy P. et al, (2018), Trials, 19
Global health trials methodological research agenda: results from a priority setting exercise.
Rosala-Hallas A. et al, (2018), Trials, 19, 48 - 48
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None. et al, (2018), The Lancet Oncology, 19, 27 - 39
Right from the start: protocol for a pilot study for a randomised trial of the New Baby Programme for improving outcomes for children born to socially vulnerable mothers.
Macdonald G. et al, (2018), Pilot and Feasibility Studies, 4, 44 - 44
Priorities for methodological research on patient and public involvement in clinical trials: A modified Delphi process
Kearney A. et al, (2017), HEALTH EXPECTATIONS, 20, 1401 - 1410